Please note – you will leave a website owned by MacroGenics, Inc.
MacroGenics is not responsible for any content on the third party website.
MacroGenics is a biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases.
MacroGenics and its collaboration partners are conducting clinical studies that explore the use of product candidates developed by MacroGenics in different cancer settings. The product candidates listed below are investigational, in that they are being evaluated in clinical trials and are not yet approved for use by regulatory authorities. Approval by regulatory authorities around the world, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), is required to make our medicine available to the patients. Therefore, our priority is to enroll patients in clinical trials in order to obtain the data required for review and approval by regulatory authorities.
Acute Myeloid Leukemia (AML) and Myeloid Dysplastic Syndrome (MDS)
Relapsed/refractory B-cell Malignancies (including diffuse-large B cell lymphoma (DLBCL), follicular lymphoma (FL), mantle-cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL)
Breast Cancer (Metastatic, HER2+)
Clear Cell Renal Cell Carcinoma
Gastric and Gastroesophageal Cancer
Non-small Cell Lung Cancer (NSCLC)
Renal Cell Carcinoma
Soft Tissue Sarcoma
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
To learn about cancer and available treatments, please visit the following: